Pastorin G, Bolcato C, Cacciari B, Kachler S, Klotz K-N, Montopoli C, Moro S, Spalluto G
Dipartimento di Scienze Farmaceutiche, Università di Trieste, Piazzale Europa 1, 34127 Trieste, Italy.
Farmaco. 2005 Aug;60(8):643-51. doi: 10.1016/j.farmac.2005.04.012.
A new series of potential adenosine receptor antagonists with a [1,2,4]-triazolo-[3,4-f]-purine structure bearing at the 1 and 3 position n-propyl groups have been synthesized, and their affinities at the four human adenosine receptor subtypes (A(1), A(2A), A(2B) and A(3)) have been evaluated. In this case the presence of n-propyl groups seems to induce potency at the A(2A) and A(3) adenosine receptor subtypes as opposed to our previously reported series bearing methyl substituents at the 1 and 3 positions. In particular the non-acylated derivative 17 showed affinity at these two receptor subtypes in the micromolar range. Indeed, preliminary molecular modeling investigations according to the experimental binding data indicate a modest steric and electrostatic antagonist-receptor complementarity.
已合成了一系列新的具有[1,2,4]-三唑并-[3,4-f]-嘌呤结构且在1和3位带有正丙基的潜在腺苷受体拮抗剂,并评估了它们对四种人类腺苷受体亚型(A(1)、A(2A)、A(2B)和A(3))的亲和力。在这种情况下,与我们之前报道的在1和3位带有甲基取代基的系列相反,正丙基的存在似乎诱导了对A(2A)和A(3)腺苷受体亚型的活性。特别是非酰化衍生物17在这两种受体亚型上表现出微摩尔范围内的亲和力。事实上,根据实验结合数据进行的初步分子模拟研究表明存在适度的空间和静电拮抗剂 - 受体互补性。